

Program Committee Chair:

E. John Wherry, University of Pennsylvania, Philadelphia, PA

Program Committee:

Anna D. Barker, Ellison Institute for Transformative Medicine, Los Angeles, CA

Fabrice Barlesi, INSERM U1030 - Gustave Roussy Institute, Villejuif, France

Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY

Deepta Bhattacharya, University of Arizona Cancer Center, Tucson, AZ

John M. Carethers, University of Michigan, Ann Arbor, MI

Robert L. Ferris, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA

Patrick D. Hsu, University of California, Berkeley, CA

Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA


Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

Louis M. Staudt, National Cancer Institute, Bethesda, MD

David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Louis P. Voigt, Memorial Sloan Kettering Cancer Center, New York, NY



PROGRAM SCHEDULE

Posters will be available for on-demand viewing starting at 9:30 am U.S. ET on Wednesday, February 3.

WEDNESDAY, FEBRUARY 3

10:00 am-10:30 am Welcome and Opening Keynote Address

10:00-10:05 (5) Welcome and Introduction of Keynote Speaker
E. John Wherry, University of Pennsylvania, Philadelphia, PA

10:05-10:30 (25) Messenger RNA vaccines
Ugur Sahin, BioNTech SE, Mainz, Germany

10:30 am-10:45 am Break

10:45 am-12:35 pm Symposium 1: Intersection of the Biology of COVID-19 and Cancer

10:45-10:50 (5) Introduction
Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY


10:50-11:20 (20+10) Coronaviral use of lysosomes for egress and its implications for the immune system
Nihal Altan-Bonnet, National Heart, Lung, and Blood Institute, Bethesda, MD

11:20-11:35 (10+5) Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses
Amy Moore, GO2 Foundation for Lung Cancer, San Carlos, CA

11:35-11:50 (10+5) The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score
Gino Dettorre, Imperial College London, London, England

11:50-12:20 (20+10) New frontiers in SARS-CoV-2 functional genomics
Nevile Sanjana, New York University Langone Medical Center, New York, NY

12:20-12:35 (15) Closing Remarks / Discussion



10:45 am-12:35 pm Symposium 2: Cancer Prevention and Early Detection during the COVID-19 Pandemic

- 10:45-10:50 (5) Introduction
Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA
- 10:50-11:20 (20+10) Challenges to cancer screening during the COVID-19 pandemic
Mary E. Reid, Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 11:20-11:35 (10+5) The impact of resuming the breast cancer screening program in the Netherlands on breast cancer incidence and stage after its discontinuation due to the COVID-19 pandemic
Sabine Siesling, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands
- 11:35-11:50 (10+5) The impact of the COVID-19 pandemic on Barrett's esophagus and esophago-gastric cancer
Anita Lavery, Queen's University Belfast, Belfast, Ireland
- 11:50-12:05 (10+5) Drive By Flu-FIT: A novel way to mitigate the decrease in colorectal cancer screening during the COVID-19 pandemic
Armenta Washington, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
- 12:05-12:35 (20+10) Breast cancer screening during the COVID-19 pandemic: Are we ready for a risk-based approach?
Katherine D. Crew, Columbia University, New York, NY

12:35 pm-1:00 pm Break

1:00 pm-2:00 pm Forum 1: Cancer Trial Design/Experience During COVID-19
Moderator: Robert L. Ferris, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA

Panelists:

- Michael G. Kurilla, National Center for Advancing Translational Sciences, Bethesda, MD
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, PA
Worta McCaskill-Stevens, National Cancer Institute, Rockville, MD



1:00 pm-2:00 pm

Forum 2: When Should Patients With Cancer Be Vaccinated?

Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

Panelists:

Grace Cordovano, Enlightening Results, West Caldwell, NJ

Jill Feldman, EGFR Resistors, Deerfield, IL

Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Jia Luo, Memorial Sloan Kettering Cancer Center, New York, NY

E. John Wherry, University of Pennsylvania, Philadelphia, PA

2:00 pm-2:15 pm

Break

2:15 pm-4:05 pm

Symposium 3: COVID-19 Immunology and Pathogenesis

2:15-2:20 (5)

Introduction

Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

2:20-2:50 (20+10)

Longitudinal immunological study of 200 COVID-19 patients

James R. Heath, Institute for Systems Biology, Seattle, WA

2:50-3:05 (10+5)

Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study

Lewis Au, The Francis Crick Institute, London, England

3:05-3:20 (10+5)

Cancer patients display diminished viral RNA clearance and altered T cell responses during SARS-CoV-2 infection

Michael Chiorazzi, Yale School of Medicine, New Haven, CT

3:20-3:35 (10+5)


Spatial profiling of lung SARS-CoV-2 and influenza virus infection identifies virus specific host responses and gene signatures

Arutha Kulasinghe, Queensland University of Technology, Brisbane, Australia

3:35-4:05 (20+10)


Immunology and animal models of COVID-19

Stanley Perlman, University of Iowa, Iowa City, IA



2:15 pm-4:05 pm Symposium 4: COVID-19 Long-term Effects and Impact on Cancer Survivorship

- 2:15-2:20 (5) Introduction
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson
Comprehensive Cancer Center (JCCC), Los Angeles, CA
- 2:20-2:50 (20+10) Long-term effects and impact of COVID-19 pandemic on cancer survivorship
Larissa Nekhlyudov, Brigham and Women's Hospital/Dana-Farber Cancer
Institute, Boston, MA
- 2:50-3:05 (10+5) Effects of demographic and behavioral factors on social isolation in a cancer
center population during COVID-19 pandemic
Shelley Tworoger, Moffitt Cancer Center, Tampa, FL
- 3:05-3:20 (10+5) Impact of the COVID-19 pandemic on social and health behaviors among
rural and urban cancer patients at Huntsman Cancer Institute (HCI)
Bailee Daniels, Huntsman Cancer Institute, Salt Lake City, UT
- 3:20-4:05 (45) Closing Remarks / Discussion



THURSDAY, FEBRUARY 4

10:00 am-10:30 am Keynote Address

- 10:00-10:05 (5) Introduction of Keynote Speaker
Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA
- 10:05-10:30 (25) Vaccine development during the COVID-19 pandemic
Peter Marks, Center for Biologics Evaluation and Research, U.S. Food and
Drug Administration, Silver Spring, MD

10:30 am-10:45 am Break

10:45 am-12:35 pm Symposium 5: Cancer Drug Repurposing to Treat COVID-19

- 10:45-10:50 (5) Introduction
Fabrice Barlesi, INSERM U1030 - Gustave Roussy Institute, Villejuif, France
- 10:50-11:20 (20+10) Host factor targeted drug discovery for SARS-CoV-2 through an international
collaboration
Nevan J. Krogan, UCSF School of Medicine, San Francisco, CA
- 11:20-11:35 (10+5) Plant viral nanoparticle-based adjuvants for cancer immunotherapy and
COVID-19 vaccines
Nicole Steinmetz, University of California, San Diego, CA
- 11:35-12:05 (20+10) Storming the Castle: Repurposing treatments for COVID-19
David Fajgenbaum, University of Pennsylvania, Philadelphia, PA
- 12:05-12:35 (30) Closing Remarks / Discussion



10:45 am-12:35 pm Symposium 6: Continuity of Cancer Care

- 10:45-10:50 (5) Introduction
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 10:50-11:20 (20+10) Impact of the COVID-19 pandemic on oncology care delivery: From screening to surveillance
Trisha Wise-Draper, University of Cincinnati, Cincinnati, OH
- 11:20-11:35 (10+5) Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study
Sheena Bhalla, Icahn School of Medicine at Mount Sinai, New York, NY
- 11:35-11:50 (10+5) Outcomes of COVID-19 in patients with cancer: Results of a prospective observational comparison of routine screening strategy versus testing based on clinical suspicion
Zhuoer Xie, Mayo Clinic, Rochester, MN
- 11:50-12:05 (10+5) Telehealth experiences of adolescent and young adult cancer patients and survivors during the COVID-19 pandemic
Karely Mann, Huntsman Cancer Institute, Salt Lake City, UT
- 12:05-12:35 (20+10) Recommendations supporting continuity of care: Landscape, perspectives, limitations, and open questions
Giuseppe Curigliano, University of Milan, Milan, Italy

12:35 pm-1:00 pm Break

1:00 pm-2:00 pm Forum 3: Adaptive Trial Design / ICU


Moderator: Marko Spasic, Parker Institute for Cancer Immunotherapy, San Francisco, CA

Panelists:

Derek C. Angus, University of Pittsburgh, Pittsburgh, PA

Laura J. Esserman, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA

Robin Mogg, Bill & Melinda Gates Medical Research Institute, Cambridge, MA



1:00 pm-2:00 pm

Forum 4: Telehealth

Moderator: Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

Panelists:

Elizabeth A. Krupinski, Emory University, Atlanta, GA

Hanna K. Sanoff, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

2:00 pm-2:15 pm

Break

2:15 pm-4:05 pm

Symposium 7: COVID-19 Vaccines

2:15-2:20 (5)

Introduction

Deepta Bhattacharya, University of Arizona Cancer Center, Tucson, AZ

2:20-2:50 (20+10)

Development of the Moderna COVID-19 vaccine

Randall N. Hyer, Moderna, Cambridge, MA


2:50-3:20 (20+10)

SARS-CoV-2 mRNA-LNP vaccines elicit potent germinal center responses associated with neutralizing antibody generation


Michela Locci, University of Pennsylvania, Philadelphia, PA

3:20-4:05 (45)

Closing Remarks / Discussion



2:15 pm-4:05 pm	Symposium 8: Critical Care and Outpatient Management of COVID-19 and Cancer Patients
2:15-2:20 (5)	Introduction Louis P. Voigt, Memorial Sloan Kettering Cancer Center, New York, NY
2:20-2:38 (13+5)	Risks and outcomes of COVID-19 in patients with cancer Mini Kamboj, Memorial Sloan Kettering Cancer Center, New York, NY
2:38-2:56 (13+5)	COVID-19: The MD Anderson Cancer Center experience Cristina Gutierrez, The University of Texas MD Anderson Cancer Center, Houston, TX
2:56-3:14 (13+5)	Managing COVID-19 severe pneumonia in cancer patients Elie Azoulay, Hôpital St Louis, Paris, France
3:14-3:32 (13+5)	Caring for patients with cancer during COVID-19: Outpatient operations Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY
3:32-3:50 (13+5)	Waiting for COVID-19: Nothing like Godot Sanjay Chawla, Memorial Sloan Kettering Cancer Center, New York, NY
3:50-4:05 (15)	Closing Remarks / Discussion



FRIDAY, FEBRUARY 5


10:00 am-10:30 am Keynote Address

- 10:00-10:05 (5) Introduction of Keynote Speaker
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- 10:05-10:30 (25) Prolonged virus shedding and virus-induced lymphopenia are detrimental in cancer patients
Laurence Zitvogel, Gustave Roussy, Villejuif, France

10:30 am-10:45 am Break

10:45 am-12:35 pm Symposium 9: Effects of Cancer Treatments on COVID-19

- 10:45-10:50 (5) Introduction
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 10:50-11:20 (20+10) CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer
Santosh A. Vardhana, Memorial Sloan Kettering Cancer Center, New York, NY
- 11:20-11:35 (10+5) High incidence of persistent Covid-19 among patients with lymphoma treated with B-cell depleting immunotherapy
Sylvain Lamure, CHU Montpellier, Montpellier, France
- 11:35-11:50 (10+5) Real world data analysis of patients with genitourinary cancers receiving systemic anticancer treatment during the COVID-19 pandemic at Guy's Cancer Centre: A single centre retrospective study in the UK
Christina Karampera, Guy's and St. Thomas' NHS Foundation Trust, London, England
- 11:50-12:05 (10+5) Asymptomatic detection of COVID-19 among cancer patients receiving infusional anti-cancer therapy
Justin Shaya, UC San Diego Moores Cancer Center, San Diego, CA
- 12:05-12:35 (20+10) Prognostic factors in cancer patients with COVID-19: Focus on systemic therapies
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA



10:45 am-12:35 pm Symposium 10: Health Inequities and Disparities in the COVID-19 Pandemic

- 10:45-10:50 (5) Introduction
John M. Carethers, University of Michigan, Ann Arbor, MI
- 10:50-11:20 (20+10) Cancer health equity & COVID-19
Karen M. Winkfield, Meharry-Vanderbilt Alliance, Nashville, TN
- 11:20-11:35 (10+5) Financial hardship and mental health among cancer survivors during the COVID-19 pandemic: An analysis of the US COVID Impact Survey
Jessica Islam, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
- 11:35-11:50 (10+5) Adolescent and young adult cancer patient and survivor employment changes during COVID-19 are associated with financial toxicity
Austin Waters, Huntsman Cancer Institute, Salt Lake City, UT
- 11:50-12:05 (10+5) Disparities in food insecurity among cancer survivors during the U.S. COVID-19 pandemic
Marlene Camacho-Rivera, SUNY Downstate Health Sciences University, Brooklyn, NY
- 12:05-12:35 (20+10) Economic and insurance challenges from the COVID-19 pandemic for individuals with cancer
Michael T. Halpern, National Cancer Institute, Bethesda, MD

12:35 pm-1:00 pm Break


- 1:00 pm-2:00 pm Forum 5: Workforce Issues**
Moderator: Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD
- Panelists:
Dinah S. Singer, National Cancer Institute, Bethesda, MD
Cheryl L. Willman, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
Robert A. Winn, VCU Massey Cancer Center, Richmond, VA

2:00 pm-2:15 pm Break




2:15 pm-4:05 pm Symposium 11: Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19

- 2:15-2:20 (5) Introduction
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY
- 2:20-2:50 (20+10) Impact of COVID-19 on recipients of cellular therapies
Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, NY
- 2:50-3:05 (10+5) Factors associated with developing COVID-19 among cancer patients in New York City
Monica Chen, Columbia University, New York, NY
- 3:05-3:20 (10+5) The impact of COVID-19 in the cancer population stratified by age: A real-world data study from Guy's Cancer Center
Rushan Sylva, Guy's and St. Thomas' NHS Foundation Trust, London, England
- 3:20-3:35 (10+5) Using CXR-Net to detect COVID-19 and non-COVID-19 patients
Abdulah Haikal, Wayne State University School of Medicine, Detroit, MI
- 3:35-4:05 (20+10) Risks of severe COVID19 infection in patients with solid tumors
Tian Zhang, Duke University School of Medicine, Durham, NC



2:15 pm-4:05 pm	Symposium 12: Epidemiology and Registries of COVID-19 and Cancer
2:15-2:20 (5)	Introduction Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA
2:20-2:35 (10+5)	Quantifying the impact of COVID-19 on cancer care: Pathology volume change in SEER cancer registries Todd Golden, National Cancer Institute, Bethesda, MD
2:35-2:50 (10+5)	Comprehensive meta-analysis of COVID-19 mortality rates for 22 cancer subtypes from the Reboot: COVID-Cancer Project, an interactive resource with aggregated data from 21,839 cancer patients Catherine Del Vecchio Fitz, Reboot Rx, Boston, MA
2:50-3:05 (10+5)	Clinical and demographic characteristics associated with shorter time to COVID-19 death Maria J. Monroy-Iglesias, King's College London, London, England
3:05-3:20 (10+5)	Covid-19 disease in patients with lung cancer in Spain: GRAVID Lung Cancer Patients Disease (GRAVID study) Jose Maria Mazarico Gallego, Hospital Universitario 12 de Octubre, Madrid, Spain
3:20-3:35 (10+5)	Prevalence of COVID-19 in asymptomatic cancer patients on active systemic treatment in a public Brazilian hospital: The impact of socioeconomic status Luiza Fadul, Hospital de Base de São José do Rio Preto, Sao Jose do Rio Preto, Brazil (Q&A may be Daniel Vilarim)
3:35-3:50 (10+5)	Social Determinants of Health (SDOH) barriers as predictors of intent to vaccinate for COVID-19 in a vulnerable population Beth A. Jones, Yale University School of Public Health, New Haven, CT
3:50-4:05 (15)	Closing Remarks / Discussion
4:05 pm-4:20 pm	Break



4:20 pm-5:30 pm

Closing Session: Emerging Topics

Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

Panelists:

Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

E. John Wherry, University of Pennsylvania, Philadelphia, PA